United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$276.26 USD
+1.13 (0.41%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $276.13 -0.13 (-0.05%) 5:16 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Brokerage Reports
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 521 - 540 ( 590 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Corporate Update: We Believe the Company Can Address Three Key Issues Causing Overhang on the Stock
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Movie Rental and Exhibitor Biweekly Newsletter-May 21 - June 3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
ATS Preview: Data Presentations Support Clinical Profiles For Adcirca, Tyvaso, Remodulin, Oral Treprostinil and Beraprost
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1:12 Revenues and Earnings Beat, 2012 Revenue Guidance Reconfirmed, Reiterate UTPERFORM and $91 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1 Preview: We Believe Consensus for Product Sales Is Achievable
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
FDA Acceptance Of Oral Treprostinil NDA Solidifies The Timing For Potential Approval In Q
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
4Q11 Results Review: Revenue Comes in Light; Reiterates Prior 2012 & 2013 Guidance
Provider: AURIGA USA
Analyst: MCDONALD P
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q4:11 Sales Choppy But FY GAAP EPS Beat. Reiterate OUTPERFORM and $91 FV as Growth Remains Intact, in our View.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q4 Preview: We Believe Consensus for Product Sales Is Achievable. Reiterate OUTPERFORM and $91 Fair Value.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
In Our View The Paragraph IV Certification For Remodulin Is Not A Near-Term Threat To Revenue Growth
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L